Cetya Therapeutics winner of bioscience venture showcase

FORT COLLINS — The Colorado Bioscience Association named Cetya Therapeutics Inc. the winner of its venture showcase at the Colorado Life Science Innovation Forum.

The Fort Collins-based company focuses on developing targeted cancer treatments through the commercialization of largazole analogs by inhibiting histone deacetylases (HDACs). HDACs are used in psychiatry and neurology as mood stabilizers and anti-epileptics; Cetya is using them for targeted cancer treatments and are using the enzyme largazole to do that.

Jennifer Jones, vice president of the Colorado Bioscience Association, presented Cetya CEO Cliff Hendrick with a $7,500 award. The award was sponsored by Dorsey & Whitney and EKS&H Capital Advisors.

SPONSORED CONTENT

People Powered: Preparing Longmont Businesses for Economic Success

Longmont Chamber and FNBO present People Powered on April 24, 2024, aiming to inform business owners about workforce development, housing, and transportation issues.

“Our team is energized to be named winner of the Colorado Life Science Innovation Forum Venture showcase,” Hendrick said. “The recognition gives our company additional momentum as we advance our oncology program.”

Two other Colorado companies competed in the event: Brava Diagnostics of Boulder and Velóce Corp. in Fort Collins.